Rossari Biotech Ltd - 543213 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the quarter ended September, 2023. Rossari Biotech Ltd - 543213 - Closure of Trading Window
Intimation of Trading Window Closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Incorporation of Rossari Bangladesh Limited, a Wholly Owned Subsidiary of the Company. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation of Transcript of the Q1 FY24 Earnings Conference Call held on July 31, 2023
Reduce Rossari Biotech; target of Rs 725: ICICI Securities
ICICI Securities recommended hold rating on Rossari Biotech with a target price of Rs 725 in its research report dated August 01, 2023. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Conference call for Q1 FY24 Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper Publication of extracts of Consolidated Un-audited Financial Results for the quarter ended June 30, 2023 Q1FY24 Quarterly Result Announced for Rossari Biotech Ltd.
Specialty chemicals company Rossari Biotech announced Q1FY24 results: Consolidated Q1FY24: Revenue from operations stood at Rs 410.6 crore as against Rs 434.7 crore EBITDA at Rs 57.7 crore as against Rs 57.8 crore EBITDA margin at 14.1% as against 13.3% PAT stood at Rs 29.3 crore as against Rs 28.7 crore EPS (Diluted) stood at Rs 5.28 as against Rs 5.18 Standalone Q1FY24: Revenue from operations stood at Rs 258.3 crore as against Rs 233.7 crore EBITDA at Rs 35.1 crore as against Rs 27.1 crore EBITDA margin at 13.6 % as against 11.6% PAT stood at Rs 21.6 crore as against Rs 15.4 crore EPS (Diluted) stood at Rs 3.90 as against Rs 2.78 Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said, “We have recorded a steady performance during the quarter, demonstrating the resilience and adaptability of our business model amidst a challenging global economic landscape. Our commitment to sustainable and innovative solutions has kept us in a stable position despite the current subdued demand scenario witnessed in the chemical markets. As a part of its digitisation initiatives, the Company during the quarter went live on SAP S/4 HANA across the Group. For this transformation to a new ERP, the Company had taken about a week’s planned shutdown in April and then about another week for system stabilisation. We are happy to inform you that the entire process happened seamlessly and the system is running smoothly. This planned migration resulted in lower sales in April 2023. We are delighted to share that during the quarter, we acquired the remaining 16% stake in our subsidiary Tristar Intermediates Private Limited and we are nearing the completion of the acquisition of the remaining stake in Unitop, leading to 100% ownership. Following these strategic moves, our intent to seamlessly integrate both Unitop and Tristar into our operations will drive growth, and enhance overall competitiveness. R&D; continues to be a cornerstone of our growth strategy and will play a pivotal role in the Company’s future roadmap. Our confidence in customised products as a differentiator is backed by our track record in developing unique and innovative solutions for our customers As the market landscape continues to evolve, we see our emphasis on R&D; and customised solutions as an important pillar in maintaining consistent growth in a volatile environment. Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. We firmly believe that our strategic initiatives focused on broadening our customer base, prioritizing higher margin segments, along with our commitment to R&D;, particularly in developing new and innovative products, position us favourably for delivering healthy operational and financial performance in the coming years." Result PDF